U.S. pharmaceutical Eli Lilly is partnering with Chinese drugmaker Shanghai Junshi Biosciences to develop new antibody therapies for COVID-19, the disease that has sickened 3.6 million people worldwide.
The companies will collaborate on therapeutic antibody research that could be used to treat and prevent SARS-COV-2, the virus that causes COVID-19, Hong Kong listed Junshi said in a statement. The deal is worth up to $330 million to Junshi.
As scientists race to develop treatments for COVID-19, neutralizing antibody therapies seem to be in the forefront due to their potential efficacy, despite substantial risks, experts say.
A neutralizing antibody recognizes proteins